Stock Analysis
- United States
- /
- Healthcare Services
- /
- NasdaqGS:WGS
GeneDx Holdings First Quarter 2024 Earnings: Beats Expectations
GeneDx Holdings (NASDAQ:WGS) First Quarter 2024 Results
Key Financial Results
- Revenue: US$62.4m (up 45% from 1Q 2023).
- Net loss: US$20.2m (loss narrowed by 67% from 1Q 2023).
- US$0.78 loss per share (improved from US$3.04 loss in 1Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
GeneDx Holdings Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 26%. Earnings per share (EPS) also surpassed analyst estimates by 50%.
Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Healthcare industry in the US.
Performance of the American Healthcare industry.
The company's shares are up 42% from a week ago.
Risk Analysis
It is worth noting though that we have found 3 warning signs for GeneDx Holdings (1 makes us a bit uncomfortable!) that you need to take into consideration.
Valuation is complex, but we're helping make it simple.
Find out whether GeneDx Holdings is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqGS:WGS
GeneDx Holdings
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services.
Excellent balance sheet with concerning outlook.